These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 20547017

  • 1. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
    Tuppurainen M, Härmä K, Komulainen M, Kiviniemi V, Kröger H, Honkanen R, Alhava E, Jurvelin J, Saarikoski S.
    Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
    [Abstract] [Full Text] [Related]

  • 2. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T, Vehmanen L, Elomaa I, Välimäki M, Mäkelä P, Blomqvist C.
    Br J Cancer; 2001 Apr 20; 84(8):1047-51. PubMed ID: 11308252
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2007 Jul 20; 23(7):398-403. PubMed ID: 17701771
    [Abstract] [Full Text] [Related]

  • 4. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy.
    Filipponi P, Pedetti M, Fedeli L, Cini L, Palumbo R, Boldrini S, Massoni C, Cristallini S.
    J Bone Miner Res; 1995 May 20; 10(5):697-703. PubMed ID: 7639104
    [Abstract] [Full Text] [Related]

  • 5. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW, Gluck OS, Lang E, Rakov V.
    Menopause; 2005 May 20; 12(6):741-8. PubMed ID: 16278618
    [Abstract] [Full Text] [Related]

  • 6. "Twice-a-month" clodronate 200 mg IM: a new dosing regimen and improved therapy adherence in the treatment of postmenopausal osteoporosis.
    Muratore M, Quarta L, Calcagnile F, Quarta E.
    Adv Ther; 2010 May 20; 27(5):314-20. PubMed ID: 20526703
    [Abstract] [Full Text] [Related]

  • 7. Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study.
    Välimäki MJ, Laitinen K, Patronen A, Puolijoki H, Seppänen J, Pylkkänen L, Aranko SM, Sairanen S, Blåfield H, Rekiaro M, Väisänen K, Kormano M, Mäkinen L, Salmi J, Ala-Kaila K, Perttilä J, Vesterinen K, Koivunoro K, Probone Study Group.
    Osteoporos Int; 2002 Dec 20; 13(12):937-47. PubMed ID: 12459936
    [Abstract] [Full Text] [Related]

  • 8. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M, Balducci S, Schiappoli A, Caliumi C, Petramala L, Cerci S, Cotesta D, D'Erasmo E, Letizia C.
    Ann Ital Med Int; 2003 Dec 20; 18(2):89-98. PubMed ID: 12886826
    [Abstract] [Full Text] [Related]

  • 9. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M, Theppisai U, Manonai J, Suchartwatnachai C, Jorgensen LN.
    Acta Obstet Gynecol Scand; 2003 Sep 20; 82(9):857-66. PubMed ID: 12911449
    [Abstract] [Full Text] [Related]

  • 10. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M, Cappagli B, Ciaponi M, Pepe A, Vacca F, Genazzani AR.
    Maturitas; 2008 Jan 20; 59(1):2-6. PubMed ID: 18063490
    [Abstract] [Full Text] [Related]

  • 11. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB, Noyan V, Yildiz A, Biberoğlu K.
    Climacteric; 2000 Jun 20; 3(2):92-101. PubMed ID: 11910657
    [Abstract] [Full Text] [Related]

  • 12. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S, Caubel P, Garnero P, Felsenberg D.
    Maturitas; 2004 Jul 15; 48(3):197-207. PubMed ID: 15207885
    [Abstract] [Full Text] [Related]

  • 13. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.
    J Bone Miner Res; 2004 May 15; 19(5):728-36. PubMed ID: 15068495
    [Abstract] [Full Text] [Related]

  • 14. Prevention of postmenopausal bone loss with long-cycle hormone replacement therapy.
    Popp AW, Bodmer C, Senn C, Fuchs G, Kraenzlin ME, Wyss H, Birkhaeuser MH, Lippuner K.
    Maturitas; 2006 Jan 20; 53(2):191-200. PubMed ID: 16368472
    [Abstract] [Full Text] [Related]

  • 15. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, Kelaghan J.
    J Bone Miner Res; 1999 Sep 20; 14(9):1583-95. PubMed ID: 10469288
    [Abstract] [Full Text] [Related]

  • 16. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM, Parviainen M, Niskanen L, Komulainen M, Tuppurainen MT, Kröger H, Saarikoski S.
    J Clin Endocrinol Metab; 1997 Aug 20; 82(8):2476-82. PubMed ID: 9253321
    [Abstract] [Full Text] [Related]

  • 17. Does vitamin D strengthen the increase in femoral neck BMD in osteoporotic women treated with estrogen?
    Tuppurainen MT, Komulainen M, Kröger H, Honkanen R, Jurvelin J, Puntila E, Heikkinen AM, Alhava E, Saarikoski S.
    Osteoporos Int; 1998 Aug 20; 8(1):32-8. PubMed ID: 9692075
    [Abstract] [Full Text] [Related]

  • 18. Levonorgestrel and 17beta-estradiol given transdermally for the prevention of postmenopausal osteoporosis.
    Warming L, Ravn P, Christiansen C.
    Maturitas; 2005 Feb 14; 50(2):78-85. PubMed ID: 15653003
    [Abstract] [Full Text] [Related]

  • 19. Early postmenopausal bone loss is associated with PvuII estrogen receptor gene polymorphism in Finnish women: effect of hormone replacement therapy.
    Salmén T, Heikkinen AM, Mahonen A, Kröger H, Komulainen M, Saarikoski S, Honkanen R, Mäenpää PH.
    J Bone Miner Res; 2000 Feb 14; 15(2):315-21. PubMed ID: 10703934
    [Abstract] [Full Text] [Related]

  • 20. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
    Bunyavejchevin S, Limpaphayom KK.
    J Med Assoc Thai; 2001 Jan 14; 84(1):45-53. PubMed ID: 11281499
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.